



*Patient Focused. Discovery Driven.*

## **Exagen Inc. To Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference**

February 3, 2021

SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 17-19, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, February 17 at 3:00 PM ET, which is accessible to conference attendees. Management will also be participating in one-on-one meetings with investors during the event; meetings can be requested through BTIG.

### **About Exagen Inc.**

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen's goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus. For further information please visit [www.exagen.com](http://www.exagen.com).

### **Forward Looking Statements**

Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen's business, including, without limitation: the COVID-19 pandemic may continue to adversely affect our business, financial condition and results of operations, including as a result of shutdowns of our facilities and operations as well as those of our suppliers and courier services, impeding patient movement and interruptions to healthcare services causing a decrease in test volumes, disruptions to the supply chain of material needed for our tests, our sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving our tests; the company's commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community; the company's ability to successfully execute on its Dx/Rx strategy, including its promotion efforts for SIMPONI®; third party payers not providing coverage and adequate reimbursement for the company's testing products or promoted therapeutics; the company's ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting the company's business; and other risks described in the company's prior press releases and the Company's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in the company's Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

### **Investors**

Westwicke Partners

Mike Cavanaugh

[Mike.Cavanaugh@westwicke.com](mailto:Mike.Cavanaugh@westwicke.com)

646.677.1838

### **Company**

Exagen Inc.

Kamal Adawi, Chief Financial Officer

[kadawi@exagen.com](mailto:kadawi@exagen.com)

760.477.5514



*Patient Focused. Discovery Driven.*

Source: Exagen Inc.